Is It Too Late to Buy Moderna and BioNTech Shares?

Moderna and BioNTech’s share prices have increased by 621% and 237% year-to-date. Is it too late to get in on these COVID-19 vaccine frontrunners?

A few weeks ago, the world rejoiced to the news that two COVID-19 vaccine trials produced extremely encouraging results.

Pharmaceutical giant Pfizer Inc (NYSE: PFE) and BioNtech (NASDAQ: BNTX) announced that their trial COVID-19 vaccine was 95% effective. In its phase III trial, out of the 170 confirmed cases of COVID-19 among the trial participants, 162 were from the placebo group, while only 8 were in the vaccine group. 

Hot on the heels of Pfizer and BioNtech’s announcement, Moderna (NASDAQ: MRNA), a young front-runner in the development of mRNA-based vaccines, announced that its own investigational COVID-19 vaccine had promising interim results. Out of 95 participants of the trial who got COVID-19, only 5 were from the vaccinated group, suggesting a 94.5% efficacy rate.

Stock markets have reacted sharply to the news. Moderna’s current share price is nearly 60% higher from the day before its vaccine announcement on 16 November 2020, while BioNtech’s share price is up by 24% since its joint announcement with Pfizer on 9 November.

Year-to-date, Moderna and BioNtech’s share prices are up by 621% and 237%, respectively.

US$200 billion opportunity

With the hype surrounding these two companies, I wanted to find out if it was too late to get in on their shares. To do so, I came up with a simple calculation to see how much the two companies could potentially earn from their vaccines.

We are currently being told that for best efficacy, two doses of the vaccines are required. There are 7 billion people in the world and to achieve herd immunity, 70% of the population (5 billion people) needs to be vaccinated.

Based on these figures, the world will need about 10 billion doses. 

The US government has placed an initial order of 100 million doses for US$1.95 billion with Pfizer and BioNTech, with the option to purchase 500 million additional doses.  That works out to US$20 per dose. Moderna has said that it will charge between US$25 and US$37 per dose.

Moderna’s market cap vs its potential profits

We can now answer the question of whether the rally in Moderna and BioNTech’s share prices are justified.

Let’s take a base case scenario that the two front runners will manage to corner 50% of the market opportunity.

If Moderna can supply 25% of the global need for COVID-19 vaccines, it will need to supply 2.5 billion doses. We can also assume that these vaccine doses will be sold over a few years. Moderna CEO Stephane Bancel said that they are on track to produce between 500 million to 1 billion doses in 2021.

For the sake of simplicity, let’s assume that Moderna will sell 500 million doses a year for five years. Based on US$25 per dose, that translates to US$12.5 billion in revenue each year.

Pharmaceutical companies can command extremely high margins, especially for a novel product that is first to the market. Given this, Moderna can possibly earn a gross margin as high as 60%, and a net margin of 40%. This will mean that Moderna could earn an annual net profit of US$5 billion based on my projected revenue figure.

Moderna currently sports a market cap of US$56 billion. Given these assumptions, it trades at around 11 times its potential annual earnings.


How About BioNTech?

BioNtech currently has a market cap of US$27.5 billion. Pfizer has agreed to pay BioNTech US$185 million in a mix of cash and Pfizer shares, and an additional US$563 million for future milestone payments.

In addition, BioNTech stands to earn 50% of the profit brought in from the sale of the vaccines.

Pfizer and BioNTech sold their first batch of vaccine doses to the US government at US$20 per dose. If they can sell a similar number of doses as Moderna and achieve similar margins, BioNTech’s share of the profit will be around US$2 billion.

Based on this scenario, BioNTech trades at 14 times this potential annual earnings.

If the above scenarios materialise, BioNTech and Moderna stand to gain a huge windfall. On top of that, their current valuations, at less than 15 times future earnings each, do not seem too demanding.

But…

… there are risks. 

First of all, not every government may be willing to pay for the vaccines to immunise their country. Governments from first world countries such as the US, UK, Malaysia, and Singapore have shown a willingness to pay for the vaccines for their citizens but other countries may not be so willing or even have the means to do so. If fewer governments bite, my estimate of a market opportunity of 10 billion doses over five years may have been overstated.

Another thing to consider is the threat of new vaccines. Competition could erode margins and lead to a lower market share than I modelled for. Pharmaceutical giants AstraZeneca and Johnson and Johnson, have pledged not to make a profit from their vaccines as long as the world is still in a pandemic. This could force companies like Moderna to lower their prices if vaccines from these companies gain approval in the coming months.

We should also not overlook the fact that the vaccines may be effective enough that patients do not need a booster every few years. In this scenario, it could be possible that after the initial demand for vaccines, and once global herd immunity is achieved, subsequent demand for vaccines will subside and earnings will dry up.

This is a legitimate concern as both BioNTech and Moderna have no other product currently in the market.

Potential tailwinds

But there are some potential tailwinds on the cards. Both Moderna and BioNTech have a healthy pipeline of drugs in development besides their COVID-19 vaccines.

The success of their COVID-19 vaccines also validates the potential of mRNA technology in other use-cases. Experts claim that mRNA-based vaccines could potentially be targeted at numerous diseases that we previously had no vaccines for. Both companies specialise in mRNA technology and could stand to benefit from this breakthrough. Moderna, for example, is working on another mRNA vaccine for CMV, which is already in phase II clinical trial.

Besides vaccines, both companies are also researching drugs that use similar mRNA technologies to treat cancer. Moderna currently has a total pipeline of 20 other drugs while BioNTech boasts a pipeline of 28. If another blockbuster drug reaches the market, they could unlock a different source of profits.

So is it too late to buy now?

Investing in young Biotech companies is risky but can be rewarding. The successful commercialisation of a single drug, as in the case of both Moderna and BioNTech, can lead to a multi-year windfall for the company and, as shown, a large appreciation in its share price.

However, there are also risks to pre-product companies.

Many may start off with a promising novel technology only to stumble at the final hurdle.

In Moderna and BioNTech’s case, they seemed to have successfully navigated the final hurdle to commercialisation by posting excellent phase III results for their COVID-19 vaccines. The market opportunity for them is huge and they are set to bring in copious amounts of cash in the not so far future.

But are investors on the sidelines too late now? With the spike in both the share prices of Moderna and BioNTech, and considering the possibility of competition, it seems that the market has already priced in a substantial amount of the future earnings from both companies’ COVID-19 vaccine.

I believe investors who are still considering investing in these two companies should not focus on the COVID-19 vaccine as this has already been priced into the stock. Instead investors should explore the pipeline of drugs and how Moderna and BioNTech plan to invest their windfall. This will be a greater determinant of the long-term returns of the company’s shares.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. We currently have no vested interest in any companies mentioned. Holdings are subject to change at any time.

Is Zoom Video Communications Overvalued?

Zoom Video Communications is one of the hottest stocks this year and is up by 460% year-to-date. Does it still have legs to run?

Zoom Video Communications Inc (NASDAQ: ZM) has been on a roll this year. The video conferencing software provider has been one of the main benefactors of the COVID-19 pandemic.

In the quarter ended 30 April 2020, Zoom’s revenue increased by a mind-boggling 169% from the corresponding period a year ago. But that wasn’t all. In the very next quarter ended 31 July 2020, Zoom again blew past expectations, reporting a 355% increase in revenue.

Unsurprisingly, investors have reacted sharply to the news, sending Zoom’s stock price up 460% since the turn of the year. As of the time of writing, the company was valued at US$114.8 billion. To put that in perspective, the Singapore stock market’s largest company by market capitalisation, DBS Group Holdings, is only valued at S$61 billion. Zoom was born just nine years ago in 2011 while DBS took 52 years to get to where it is today.

The question now for investors is whether Zoom is overvalued. 

Growth skeptic

In March this year, I preached conservatism when it came to Zoom. The company, then, had a market cap of around US$38 billion. It had just doubled in value and I was concerned that investors were getting too optimistic. 

Looking back, I was way too conservative in my growth projections. Zoom went on to blow past consensus expectations in the two quarters after that, as I had described earlier, far exceeding what some of the biggest bulls had expected.

Zoom has become more than just a company, it has become a verb. Even my non-techy parents use “Zoom” as a synonym for video conferencing.

Since my article, Zoom has more than quintupled in value. After seeing the quick pace of adoption, my blogging partner, Ser Jing, and I decided that Zoom was worthy of a place in our investment fund’s portfolio.

We bought our first tranche of shares at US$254, which was then close to an all-time high and have added more since. Today, Zoom’s shares trade at around US$404.

Believing

I used to be one of the sceptics when it came to Zoom’s valuation but I am now firmly in the opposite camp. In fact, I think that even after the recent run-up in its share price, Zoom can still provide significant value for long-term investors.

Zoom exited the quarter ended 31 July 2020 with an annual revenue run rate of US$2.6 billion. Unlike many high-growth software companies, Zoom boasts not just GAAP profitability, but also a high free cash flow margin. In that quarter, it had a free cash flow margin of 56%. Boosted by record collections during the quarter, Zoom’s cash flow margin is best-in-class for software companies.

Even after accounting for any one-off jump in collections for the quarter, I think Zoom can settle at a free cash flow margin of close to 40% at its steady state.

Given this, and using Zoom’s annual revenue run rate, Zoom currently trades at a normalised price-to-annual free cash flow run rate multiple of 110. By most accounts that seems like a high multiple to pay. But let’s not forget that Zoom has immense business momentum in its favour. The company just grew by a staggering 355% in the last quarter and in its recent Zoomtopia customer and investor day event, the company let slip that usage is up since then.

Can Zoom continue to grow?

Zoom has undoubtedly been one of the benefactors of shelter-in-place measures enacted by governments around the world to combat COVID-19. But even after life returns to normal, I believe Zoom will still be a mainstay for most companies. Video conferencing has become a norm due to the ease and practicality of its use. In fact, many companies have announced that they will permanently adopt work-from-home or hybrid work settings, allowing employees to spend either all or part of their time working from home.

Although Zoom’s growth will understandably slow when the pandemic passes, I believe the company will still see decent growth well into the future as video conferencing becomes even more prevalent for businesses and individuals alike.

Zoom is also barely scratching the surface of its total addressable market. In its IPO prospectus released last year, Zoom stated that it is addressing a US$42 billion communications market, according to independent market researcher International Data Corporation. But I believe the US$42 billion figure understates the increasing number of use cases that video conferencing addresses. The pandemic has demonstrated that video conferencing software can be used for education, telemedicine, fitness classes, and many more purposes than previously imagined. 

Given the momentum in video conferencing, I think it is not beyond Zoom to quadruple its annual revenue and free cash flow run rate in five years to north of US$10 billion and US$4 billion respectively.

Zoom’s current valuation is, hence, just 28 times that projected free cash flow in 2025. More importantly, I don’t see its growth stopping there. Zoom’s CEO, Eric Yuan, and his crew are highly innovative and have already recently released new products such as Zoom Phone and Zoom hardware to expand its addressable market. 

Final words

From a trailing-12-months perspective, Zoom seems immensely overvalued. However, for a company that is growing as fast as Zoom is, the next 12 months will look very different from the last 12, so we certainly shouldn’t be looking backwards to come up with a valuation.

Looking beyond the next 12 months, Zoom’s growth will likely endure as it seeks to win its share of the more than US$42 billion market opportunity ahead of it. Competition remains a threat to Zoom, given that Zoom users can just as easily switch to an alternate software. But I believe that Zoom’s relentless pursuit of customer satisfaction and its superior product gives it a big leg up over its competitors. Zoom boasts a net promoter score of 62, the highest among video conferencing software that I’ve seen. 

Zoom’s branding is also remarkably strong at the moment. Like Google, Zoom has become a verb, which is a fact that shouldn’t be underestimated.

Although there is invariably a chance that Zoom can lose its focus on satisfying customer, and competition can erode growth, the pie is large enough for multiple winners in this space. Given all this, and the momentum behind Zoom, I think that the odds of its success far outweigh the risks. For more on Zoom, you can head here to find an investment thesis for the company that Ser Jing and I have penned for our investment fund.

DisclaimerThe Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. I currently have a vested interest in Zoom Video Communications. Holdings are subject to change at any time.

How Many Stocks Should You Own?

What is the ideal level of diversification to help us balance risk and long-term returns? Here are some things to consider.

One of the age-old questions in investing is how widely should we diversify. Unfortunately, it seems that even the best investors can’t seem to agree on this.

Legendary investor Charlie Munger is famous for being a supporter of a concentrated portfolio. He once said:

“The idea of excessive diversification is madness. Wide diversification, which necessarily includes investment in mediocre businesses, only guarantees ordinary results.”

In 2017, Munger said that he owned just three positions in his personal portfolio – Berkshire Hathaway, Costco, and an investment in Li Lu’s investment partnership (which itself is highly concentrated).

At the opposite corner, we have other renowned investors who practised wide diversification and yet still achieved stunning results. For example, there’s Peter Lynch, who earned a 29.2% annualised return in his 13-year tenure managing the Fidelity Magellan Fund from 1977 to 1990. In his later years managing the fund, Lynch held as many as 1,400 stocks in the portfolio. 

Concentration and the risks

I recently had a short conversation with a friend on this topic of diversification. My friend is a proponent of having a concentrated portfolio, believing that we should not dilute our best investment ideas.

I agree that a concentrated portfolio may give you the best chance of higher returns. If you manage to build a sizeable position in a stock that becomes a multi-bagger (meaning a stock with a return of 100% or more), your return will obviously be better than if you had diluted your portfolio with other companies that ended up with lousier gains.

But we shouldn’t ignore the fact that having a concentrated portfolio can also magnify our losses. If your concentrated portfolio included a large position in a “big loser”, or perhaps in a fraud case such as Luckin Coffee, your portfolio-level return will very likely lag a more diversified portfolio.

Higher concentration = Higher variance

According to research by Alex Bryan from Morningstar, there is no real significance between a fund’s portfolio-concentration and performance.

What Bryan’s research did conclude was that more concentrated funds had a wider variance of returns. This means that concentrated funds had a higher chance of “blockbuster” returns but also had a higher risk of ending up with very poor performance. Bryan explains (emphases are mine):

“The risk in manager selection actually increases with portfolio concentration. So, while we didn’t find a link on average between performance and concentration, the dispersion of potential outcomes increases with portfolio concentration. So, really highly concentrated managers can miss the mark by a really, really wide range.

I think the other point to remember is that more highly concentrated portfolios tend to have greater exposure to firm-specific risk, and on average, that’s not well-compensated. So, again, you really want to keep an eye on risk and make sure that the manager that you hire is taking adequate steps to try to manage that risk that comes with concentration.”

How does this relate to the individual investor?

At the end of the day, how concentrated our portfolios should be depends on our risk appetite, skill, goals and ability to take on risk.

The more concentrated our portfolios, the greater the possibility of extreme returns – both on the upside and the downside. Are you willing to take on this risk and can you mitigate the risks with your ability to select stocks? These are some questions to ask yourself.

Ultimately, thinking about your needs, investment expertise, and circumstance will help you decide what level of concentration works best for you.

DisclaimerThe Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. I currently have a vested interest in Costco.

Compounding: How it Works and Why Diversification is Key

Compounding is the key to building wealth. How does it work and how can we harness it for ourselves?

Compounding is amazing, isn’t it? Just look at the graph below. It shows the nominal growth of the S&P 500, a prominent US stock market barometer, in the last 150 years.

Source: Line chart using Robert Shiller’s S&P 500 data

What’s interesting about the chart is that the S&P 500’s growth accelerated over time. That’s exactly how compounding works. Nominal growth starts off slow but increases over time.

The chart below of the S&P500 over the last 150 years shows the same thing as above, but in logarithmic form. It gives a clearer picture of the percentage returns of the stock market over the same time frame.

Source: Line chart using Robert Shiller’s S&P 500 data

The log-chart of the S&P 500 over the past 150 years is a fairly straight line up. What this tells us is that even though the return of US stocks have accelerated nominally, there was a fairly consistent growth in percentage terms over the time studied.

How do stocks compound?

This leads us to the next question. How?

In order to produce a 10% annual return for shareholders, a company that has a market value of $1 million needs to create $100,000 in shareholder value this year. The next year, in order to compound at the same rate, the company now needs to create $110,000 in shareholder value.

That figure grows exponentially and by year 30, the company now needs to create $1,586,309.30 to keep generating a 10% increase in shareholder value.

On paper, that seems outrageous and highly improbable. However, based on the historical returns of the stock market, we see that the S&P 500 has indeed managed to achieve this feat.

The reason is that companies can reinvest the capital they’ve earned. A larger invested capital base can result in larger profits. As long as they can keep reinvesting their earned capital at a similar rate of return, they can keep compounding shareholder value. 

But here’s the catch…

Although I’ve given an example of how a company can compound shareholder value over time, it really is not that simple.

Not all companies can create more shareholder value every year. In reality, corporations may find it hard to deploy their new capital at similar rates of return. Businesses that operate in highly competitive industries or are being disrupted may even face declining profits and are destroying shareholder value each year if they reinvest their capital into the business.

In fact, most of the returns from stock market indexes are due to just a handful of big winners. In 2014, JP Morgan released an interesting report on the distribution of stock returns. The report looked at the “lifetime” price returns of stocks versus the Russell 3000, an index of the biggest 3000 stocks in the US over a 35-year period.

What JP Morgan found was that from 1980 to 2014, the median stock underperformed the Russell 3000 by 54%. Two-thirds of all stocks underperformed the Russell 3000. The chart below shows the lifetime returns on individual stocks vs Russell 3000 from 1980 to 2014.

Source: JP Morgan report

Moreover, on an absolute return basis and during the same time period, 40% of all stocks had a negative absolute return.

Even stocks within the S&P 500, a proxy for 500 of the largest and most successful US-listed companies, exhibited the same. There were over 320 S&P 500 deletions from 1980 to 2014 that were a consequence of stocks that failed, were removed due to substantial declines in market value, or were acquired after suffering a decline. The impressive growth you saw in the S&P 500 earlier was, hence, due to just a relatively small number of what JP Morgan terms “extreme winners”.

That’s why diversification is key

Based on JP Morgan’s 2014 report, if you picked just one random stock to invest in, you had a 66% chance to underperform the market and a 40% chance to have a negative return.

This is why diversification is key.

If historical returns are anything to go by, diversification is not just safer but also gives you a higher chance to gain exposure to “extreme winners.” Just a tiny exposure to these outperformers can make up for the relative underperformance in many other stocks.

Last words

Compounding is a game-changer when it works.

But the reality is that not all stocks compound in value over a long period of time. Many may actually destroy shareholder value over their lifetime. A useful quote from Warren Buffet comes to mind: “Time is the friend of the wonderful business, the enemy of the mediocre.”

Given the wide divergence of returns between winners and losers, we can’t take compounding for granted. By diversifying across a basket of stocks with a sound investment framework, or by buying a fund that tracks a broadly-diversified market index, we reduce our downside risk and increase our odds of earning positive returns.

DisclaimerThe Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

Tesla is Making Virtually All Its Profits From Selling Credits. How? And Can it Last?

Tesla made US$1 billion from selling regulatory ZEV credits in the past 12 months. Can it continue and what will happen when it dries up?

Tesla recorded another profitable quarter in the second quarter of 2020, marking a fourth consecutive quarter of GAAP (generally accepted accounting principles) profit for the company. It was a welcome change for the previously cash burning and unprofitable electric vehicle pioneer. 

But eagle-eyed investors will have noticed that virtually all of Tesla’s profit and free cash flow generated over the last 12 months was due to the sale of ZEV (Zero Emission Vehicle) credits.

The company booked US$1.05 billion from the sale of regulatory ZEV credits in the 12 months ended 30 June 2020. During the same time period, Tesla recorded US$368 million and US$907 million in net profit and free cash flow, respectively.

So what are regulatory ZEV credits?

To incentivise automobile manufactures to sell ZEVs, some states in the USA have adopted a regulatory credits program, termed the ZEV Program. The ZEV Program is a state law, which currently applies to 12 states in the USA.

This law mandates that a certain percentage of each automobile manufacturer’s annual sales must be made up of zero-emission vehicles, measured by what is termed ZEV credits. ZEV credits can be earned by selling ZEVs such as battery and hydrogen fuel cell electric vehicles or Transitional Zero-Emission Vehicles (TZEV) which include hybrid vehicles.

How Tesla makes money from the ZEV program

In order to avoid penalties, manufacturers who sell in states which impose the ZEV program need to earn a certain number of ZEV credits.

There are two ways to achieve this. Either they sell sufficient ZEVs and TZEVs to chalk up enough credits, or they can buy ZEV credits from manufacturers who have built up excess ZEV credits to sell.

This regulation works beautifully for Tesla. As every vehicle sold by Tesla is a long-range electric vehicle, it generates a lot more ZEV credits than it requires. As such, it can sell excess credits to other automobile companies who need them, earning Tesla extra income at virtually no additional expense.

Can Tesla keep selling ZEV credits?

But how long can this last? Historically, Tesla’s revenue from ZEV sales has increased as more states started imposing the ZEV program.

The ZEV program originated in California in 1990 and has since extended to a total of 12 states in the US. There are a few things to consider here.

First, is the speed of regulatory changes. Tesla can benefit if more states start to impose the ZEV program.

Similarly, Tesla benefits if states that are already imposing the ZEV program increase the credit requirements. For example in California, ZEV targets are expected to rise from 3% of sales to around 8% by 2025.

Another near-term tailwind is that some credits that were bought in the past are due to expire. A recent report by EPA found that some large automakers buy credits in advance to satisfy future requirements. Some of the “banked” credits are set to expire at the end of 2021 if not used. This might result in a rush for ZEV credits in the next few years.

But it won’t last…

However, selling ZEV credits will likely not be a long-term revenue driver for Tesla. Traditional ICE (internal combustion engine) automobile makers are shifting more of their resources towards ZEVs and TZEVs. As their sales mix shifts, they will eventually be able to comply with the ZEV program without having to buy additional ZEV credits.

At Tesla’s analyst briefing for 2020’s second quarter, Chief Financial Officer Zachary Kirkhorn said:

“We don’t manage the business with the assumption that regulatory credits will contribute in a significant way to the future. I do expect regulatory credit revenue to double in 2020 relative to 2019, and it will continue for some period of time. But eventually, the stream of regulatory credits will reduce.”

Tesla can live without this extra income

Tesla is still in the early innings of its grand plan for fully-autonomous vehicles. It also has the ability to keep raising more capital through the sale of its high-flying stock.

Shareholders will also note that Elon Musk said that its autonomous software could be valued as much as US$100,000 per vehicle. With a growing base of Tesla vehicles, which are fitted with autonomous vehicle hardware, Tesla has a ready base of customers to up-sell a much higher margin software product.

In the meantime, the sale of ZEV credits can continue to be a source of cash for the next few years as the company bridges for the next phase of its business. Hopefully for shareholders, by the time the sale of ZEV credits dry up, Tesla’s other businesses will exhibit greater profitability and higher margins to keep the company’s profits and cash flow streaming in.

DisclaimerThe Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

How Does The Distribution of Outcomes Affect Our Investing Decisions

We make our investing decisions using probability. Probability distribution curves can help us understand how to gauge a stock’s risk and expected value.

When we invest in a company’s shares, we are making a long-term bet that the share price will rise over time. But in investing, we never deal in absolutes but rather a range of probable outcomes.

This is where understanding the concept of a distribution of possible outcomes becomes useful. Using what we know now, we can build a simple distribution model of long-term returns. This will, in turn, guide us on whether a stock makes a good investment and if so, how much capital should we allocate to it. Here are some common distribution model graphs and how they impact our investing decisions.

Normal distribution

This is the most common probability distribution curve. Let’s assume that a stock is expected to double after 10 years. The distribution curve for a stock with a normal distribution of returns will look something like this:

Source: My illustration using Sketch.io

In this scenario, the highest probability is for the stock to return 100%. There is also a chance that the stock can have lower or higher returns.

A narrower distribution of outcomes

There is also the possibility that a stock has a narrower distribution curve.

Source: My illustration using sketch.io

In this scenario, the variance of return for this stock is less. This means it is less likely to deviate from the expected 100% return over the time period.

We can say that this stock is less risky than the first one. Each stock may exhibit different degrees of the normal distribution curve. The thing to keep in mind here is that the taller the peak, the lower the variance and vice versa. So a very flat curve will mean the stock has a high variance of returns and is riskier. Bear in mind that these distribution curves are modelled based on our own analysis of the company.

Bimodal distribution

There are also stocks that have a bimodal distribution. This means that there are two peaks or two likely outcomes along with a range of other outcomes that cluster around the two peaks.

Source: My drawing using sketch.io

In the above example, the stock’s returns cluster around two peaks, -80% and +300%. The numbers are arbitrary and are just numbers I picked randomly. The point I am trying to make is that bimodal distribution can occur when there are two distinct possibilities that can either make or break a company.

A useful example is a biotech stock that requires FDA approval to commercialise its product. If it succeeds in getting FDA approval, the stock can skyrocket but if it is unable to get the regulatory green light, it may run out of money and the stock price can fall dramatically.

How to use probability distribution curves?

We can use a probability of outcomes distribution model to make investment decisions for our stock portfolio.

For instance, you may calculate that a stock such as Facebook Inc has a 10-year expected return of 200% and has a narrow normal probability curve. This means that the variance of returns is low and it is considered a less risky stock.

On the other side of the coin, you may think that a stock such as Zoom Video Communications can exhibit a normal distribution curve with a modal return over 10 years of 400%. But in Zoom’s case, you think it has a wider variance and a flatter distribution curve.

In these two scenarios, you think Zoom will give you better returns but it has a higher probability of falling short and a much fatter tail end risk.

Source: Sketch using sketch.io

With this mental model, you can decide on the allocation within your portfolio for these two stocks . It won’t be wise to put all your eggs into Zoom even though the expected return is higher due to the higher variance of returns. Given the higher variance, we need to size our Zoom position accordingly to reflect the bigger downside risk.

Similarly, if you want to have exposure in stocks with bi-modal distribution, we need to size our positions with a higher risk in mind. Some stocks that I believe have bimodal distribution curves include Moderna, Novocure, Guardant Health and other biotech firms that are developing novel technology but that have yet to achieve widespread commercialisation.

Portfolio allocation

As investors, we may be tempted to invest only in stocks with the highest expected returns (ER). This strategy would theoretically give us the best returns. But it is risky.

Even diversifying across a basket of such high variance stocks may lead to losses if you are unfortunate enough to have all these stocks end up below the ER you modelled for.

Personally, I prefer having a mix of both higher ER stocks and stocks that have slightly lower ER but lower variance profile. This gives the portfolio a nice balance of growth potential and stability.

DisclaimerThe Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. I currently have a vested interest in Facebook Inc and Zoom Video Communications.

My Favourite Blogs to Better Understand Software Companies

Here are some great blogs and websites for investors to help them better understand the technicalities behind software companies.

For non-software engineers like me, the topic of software can be extremely difficult to grasp. The mechanics and use case of a company’s software, where it is hosted, how the software is used or how it is different from the competition, can be complex. This is especially so for enterprise software that non-tech folks never have the chance to interact with.

Although I’ve read my fair share of IPO prospectuses and annual reports of software companies, many terms may still confuse me. But not investing in software companies because you don’t understand them can severely handicap your returns. Software companies today are highly prized due to their highly recurring revenue model, rapid growth, and expanding addressable markets.

As such, I occasionally turn to blogs and websites from experts who are able to explain the technicalities more clearly. Here are three such sites that I turn to understand software companies.

Site No.1

Software Stack Investing is a blog run and written by Peter Offringa. Peter has a rich history in the software space, leading software engineering teams for Internet-based companies for 20 years and serving as CTO at a number of companies.

His blog posts are long and highly technical but he tries to explain as much of it as simply as possible so that even the layperson can understand.

One of the highlights of his blog is his transparency. He states what stocks he bought and sold and he also incorporates his own personal views on companies and how he thinks they will perform five years out.

Peter does a thorough competitive analysis for every company he covers which gives the reader a better understanding of how one company’s software compares with another.

In his blog, he covers stocks such as Datadog, Alteryx, Fastly, Twilio, Cloudfare, MongoDB, Elastic, Okta and Docusign.

Most of these stocks offer enterprise software, which may be more technical than consumer software companies. As such, Offringa’s blog post helps fill a huge information gap for non-tech experts.

Site No.2

Stratechery is probably one of the more well-known blogs focused on technology and media businesses. It is run by Ben Thompson, who worked at Apple, Microsoft and Automattic.

His blog covers much more than pure-play software companies. But when he does cover software companies, he does a great job in breaking down what they do and how they match up to other software.

Some of his work requires a subscription. Nevertheless, the free content on his blog alone already provides great analysis and tools if you are looking for a place to read about tech and software companies.

Site No.3

The Investor’s Field Guide is a website run by Patrick O’Shaughnessy who is also the CEO of the asset management company, O’Shaughnessy Asset Management, that is founded by his father, Jim.

The website contains a collection of podcasts (and transcripts) on his interviews of some of the world’s top professionals in their respective fields. He has interviewed leaders of venture capital firms, CEOs of tech companies, psychologists and other business experts who provide deep insight into their area of expertise.

Naturally, software is one of the topics that he has covered. Some of the more recent podcasts on software include an interview with Eric Vishria, a partner at renowned venture capital firm Benchmark Capital, and joint interviews with Chetan Puttagunta, another partner at Benchmark Capital, and Jeremiah Lowin, the founder of Prefect, an open-source data engineering software company.

DisclaimerThe Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. I currently have a vested interest in Datadog, Alteryx, Twilio, MongoDB, Okta and Docusign..

Can A Stock Be Considered Cheaper Even Though Its Price Went Up?

Does a stock going up in price automatically make it more expensive?

If the price of a company’s stock went up, it’s more expensive, right? Well, not exactly. Stocks are not something static. Stocks represent part-ownership of an actual and ever-changing company.

Because the underlying company changes, its value may go up or down. If a company’s share price rises slower than its intrinsic value, the stock may have actually gotten cheaper even after the price increase.

What determines intrinsic value?

Most investors agree that a company’s intrinsic value is determined by the company’s cash on hand and the future free cash flows that it can generate. This cash can be used to grow the company or returned to shareholders through buybacks or dividends.

Investors often use historical price-to-earnings and price-to-free cash flow ratios as a proxy to gauge how cheap or expensive a company is.

Facebook shares

Facebook is an example of a stock whose price has risen, but that has actually gotten cheaper based on its earnings and free cash flow multiples.

The chart below shows Facebook’s stock price against its price-to-earnings (P/E) and price-to-free cash flow (P/FCF) multiples over the last five years.

Source: Ycharts

The blue line is Facebook’s stock price. In the last five years, Facebook’s stock price has climbed 220% from US$88.26 to US$282.73.

The red and orange lines show the social media giant’s P/E and P/FCF ratios over the years. As you can see, the P/E ratio has trended downwards, while the P/FCF flow ratio has remained largely flat. This is because the growth in Facebook’s earnings and free cash flow over the last five years has outran and kept pace, respectively, with the rise in the company’s share price. As such, based on these valuation multiples, Facebook shares can actually be considered cheaper today than they were five years ago, even though the price is higher.

Buying stocks with high valuations

The Facebook example highlights that buying a stock at a high P/E ratio may still reap good returns for investors.

In the past, Facebook shares traded at much higher P/E ratios than they do today. Yet buying shares then, still resulted in solid returns.

What this tells us is that if we buy into a quality company that can grow its free cash flow and earnings at a fast rate, even a compression in the stock’s valuation ratios will still lead to strong share price performance.

Final words

Investors often confuse stock price movements as a change in the relative cheapness of a company. If the price of a stock rises, we assume it has become more expensive and vice versa. However, that completely misses the bigger picture.

The difference between a company’s stock price and future intrinsic value is what makes a company cheaper or more expensive.

We should, therefore, put more emphasis assessing whether the company can grow its earnings and free cash flow and the longevity of their growth runway, rather than looking at the recent price movement of a stock.

DisclaimerThe Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. I currently have a vested interest in Facebook.

Can We Trust An Auditor’s Report?

Accounting scandals at Luckin Coffee and Wirecard have caused investors billions of dollars. How can we prevent such a situation from happening to us?

Accounting scandals have been in the spotlight in recent months. Companies such as Wirecard and Luckin Coffee are two of the more recent high profile cases that have cost investors billions of dollars.

Worryingly, both companies were given a pass from reputable auditors before their respective cases blew up. As investors, we rely on external auditors to give us a sense of the company’s financial well being. But with the latest scandals, can we truly trust an auditor’s stamp of approval?

Nothing new

There have been many high profile accounting scandals over the past few decades. 

One major example that comes to mind is the accounting scandal of Waste Management Inc. In 1998, the company was revealed to have faked over US$1.7 billion in earnings from 1992 to 1997. Then CEO, A. Maurice Meyers was eventually found guilty along with other top executives and the SEC (Securities & Exchange Commission) fined Arthur Anderson, the company’s auditor, over US$7 million.

But the case that truly shocked the world came a few years later in 2001- Enron. Enron was a US energy, commodities, and services company. In that year, it was discovered that the company had been using accounting loopholes to hide billions of dollars of bad debt, while inflating earnings. Within a year, Enron lost US$74 billion in market capitalisation. Its auditor was again Arthur Anderson, which by then had lost so much of its reputation that it was forced to dissolve.

Recent scandals 

You would thought that the demise of Arthur Anderson would have brought a swift change to the industry. And yet, more than two decades later, we still hear of major scandals rocking the financial world.

Earlier this year, the China-based but US-listed coffee chain, Luckin Coffee, admitted that at least US$310 million of its sales over the previous three quarters were fabricated.

Today, Luckin Coffee’s shares have been delisted from the NASDAQ exchange where they were previously listed, and the company’s survival is in serious doubt. One of the company’s major shareholders is none other than GIC, one of the Singapore government’s investment arms, owned 5.37% of the Chinese company as recently as March 2020.

The other big-name scandal this year was Wirecard, a high flying payment solutions company that is headquartered and listed in Germany. It was considered one of Germany’s tech success stories and was briefly included in the country’s main stock market bellwether, the DAX index.

However, on 25 June this year, Wirecard filed for insolvency after revealing that €1.9 billion in cash was missing from its coffers. One of the company’s largest investors is Softbank, which injected €900  million cash in 2019. Softbank has since joined efforts with Wirecard’s other investors to pursue legal action against the company’s auditor, EY.

Worrying for investors

Although the vast majority of companies are free from accounting fraud and investors can fully trust whatever they see on the financial statements, these recent accounting scandals cast a shadow of doubt for investors.

Both Wirecard and Luckin Coffee were audited by reputable auditors and yet both managed to distort their financial statements. Even professional investors such as GIC and Softbank were badly burnt.

Most worryingly, Wirecard reportedly managed to hide the missing cash from auditors for years. As investors, we often look at the cash statement as the most reliable piece of information because cash is traditionally the hardest to manipulate. And yet, Wirecard was able to mislead investors that they had more than US$2 billion in cash, which they didn’t.

What other steps can we take

As investors, we usually look to the auditor’s report as the source of truth. They are supposed to be our neutral insiders. Yet, the past few scandals have shown that sometimes an auditor’s stamp of approval is simply not enough.

So what more can we as investors do?

I think as investors, it is difficult to sniff out whether a company’s financial statements are legitimate. Even big-name investors may end up betting on the wrong horse. The best we can do is to look at trends and market data. For instance, investors should look at the past track record of the company, the background of the managers, and where the company is audited and listed.

If anything seems amiss or too good to be true, our danger-radar should be up.

Portfolio sizing is also important to try to reduce the risk of accounting scandals. Having a sufficiently diversified portfolio and sizing down a position that you think has a greater risk of fraud ensures that if you are unfortunate enough to bet on a fraudulent company, your portfolio as a whole will still not be severely impacted. 

A call for change

Based on recent scandals, we can see the clear conflicts of interest for auditors. Auditing firms are paid by the company that they are auditing, and these contracts may be worth millions of dollars. 

To protect their nest egg, auditors could be under pressure to turn a blind eye on accounting malpractice, as was the case in the Enron scandal.

Changes, therefore, need to be made in the way companies are audited. The conflicts of interest create an unnecessary incentive and can be the reason why accounting fraud may take such a long time to be detected.

Regulatory bodies need to find a way to reduce these conflicts of interest to prevent accounting scandals that not only hurt investors but the integrity of the financial markets as a whole.

Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life.

How Should We Measure The Dilutive Impact Of Stock-Based Compensation

How do we measure the impact of stock-based compensation? It may not result in a cash expense but it certainly has an impact on shareholder returns.

Many tech companies nowadays use stock-based compensation to reward managers and employees. Some even pay as much as 80% of executive pay in stocks or options. I’m personally a fan of stock-based compensation for a few reasons.

A fan

For one, stock-based compensation is not a cash expense. Cash is the lifeblood of a company and is vital for a fast-growing business.

Second, stock-based compensation aligns management’s interests with shareholders. Executives and employees become shareholders themselves who are incentivised to see the stock perform well.

In addition, companies may pay executives through stock options or restricted stock units that vest over a few years. With a multi-year vesting period, executives are incentivised to see the stock do well over a multi-year period, which aligns their interests with long-term shareholders.

All these being said, stock-based compensation does create a headache for analysts: It leads to a mismatch between the company’s profit/loss and its cash flow.

Stock-based compensation is recorded as an expense in the income statement but is not a cash expense. As such, companies who use stock-based compensation end up with higher cash flow than profits.

Why adjusted earnings is not good enough

To account for the difference, some companies may decide to provide adjusted earnings. This is a non-GAAP accounting method that adjusts earnings to add back the stock-based compensation and other selected expenses.

The adjusted earnings figure is closer to the company’s actual cash flow. But I don’t think this is the best method to measure the impact of stock-based compensation.

Adjusted earnings do not take into account the dilutive impact from stock-based compensation.

Free cash flow per share may be the best metric to use

So how do we best measure the impact of stock-based compensation? Amazon.com’s founder, Jeff Bezos once said,

Percentage margins are not one of the things we are seeking to optimize. It’s the absolute dollar free cash flow per share that you want to maximize.”

I completely agree. With the growing use of stock-based compensation, earnings per share is no longer the most important factor. Free cash flow per share has become the more important determinant of what drives long term shareholder value.

This takes into account both non-cash expenses and the dilutive impact of share-based compensation. By comparing a company’s free cash flow per share over a multi-year period, we are able to derive how much the company has grown its free cash flow on a per-share basis, which is ultimately what shareholders are interested in.

Ideally, we want to see free cash flow growing much faster than the number of shares outstanding. This would lead to a higher free cash flow per share.

Conclusion

To sum up, stock-based compensation is a good way to incentivise managers to act on the interests of shareholders.

However, it creates a challenge for analysts who need to analyse the performance of the company on a per-share basis.

In the past, earnings used to be the best measure of a company’s growth. But today, with the growing use of stock-based compensation, free cash flow per share is probably a more useful metric to measure a company’s per-share growth.

By measuring the year-on-year growth in free cash flow per share, we can derive the actual growth of a company for shareholders after accounting for dilution and any other non-cash expenses.


Disclaimer: The Good Investors is the personal investing blog of two simple guys who are passionate about educating Singaporeans about stock market investing. By using this Site, you specifically agree that none of the information provided constitutes financial, investment, or other professional advice. It is only intended to provide education. Speak with a professional before making important decisions about your money, your professional life, or even your personal life. We have a vested interest in Amazon.com shares.